Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1260

1.

Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients.

Herbrink M, Nuijten M, Nuijen B, Huitema ADR, Beijnen JH, Hendriks VM, Blanken P, Janmohamed A, van den Brink W.

J Clin Psychopharmacol. 2018 Jun;38(3):212-217. doi: 10.1097/JCP.0000000000000862.

PMID:
29620701
2.

Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry.

Spatari C, Li W, Schinkel AH, Ragno G, Schellens JHM, Beijnen JH, Sparidans RW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Apr 15;1083:204-208. doi: 10.1016/j.jchromb.2018.03.014. Epub 2018 Mar 9.

3.

A multi-gram-scale stereoselective synthesis of Z-endoxifen.

Milroy LG, Koning B, Scheppingen DSV, Jager NGL, Beijnen JH, Koek J, Brunsveld L.

Bioorg Med Chem Lett. 2018 May 1;28(8):1352-1356. doi: 10.1016/j.bmcl.2018.03.008. Epub 2018 Mar 13.

4.

Palladium-induced granulomas analysed with inductively coupled plasma mass spectrometry.

Marsidi N, Beijnen JH, van Zuuren EJ.

Contact Dermatitis. 2018 Mar 1. doi: 10.1111/cod.12979. [Epub ahead of print] No abstract available.

PMID:
29492982
5.

Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.

Derissen EJB, Huitema ADR, Rosing H, Schellens JHM, Beijnen JH.

Br J Clin Pharmacol. 2018 Feb 16. doi: 10.1111/bcp.13557. [Epub ahead of print]

PMID:
29451684
6.

The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases.

Jacobs BAW, Snoeren N, Samim M, Rosing H, de Vries N, Deenen MJ, Beijnen JH, Schellens JHM, Koopman M, van Hillegersberg R.

Eur J Clin Pharmacol. 2018 Feb 11. doi: 10.1007/s00228-018-2426-4. [Epub ahead of print]

PMID:
29430582
7.

Ultra-sensitive LC-MS/MS method for the quantification of gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma for a microdose clinical trial.

van Nuland M, Hillebrand MJX, Rosing H, Burgers JA, Schellens JHM, Beijnen JH.

J Pharm Biomed Anal. 2018 Mar 20;151:25-31. doi: 10.1016/j.jpba.2017.12.048. Epub 2017 Dec 26.

PMID:
29294409
8.

Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS.

Verheijen RB, Thijssen B, Rosing H, Schellens JHM, Nan L, Venekamp N, Beijnen JH, Steeghs N, Huitema ADR.

Ther Drug Monit. 2018 Apr;40(2):230-236. doi: 10.1097/FTD.0000000000000479.

PMID:
29256969
9.

Enrichment of Circulating Endothelial Cells by CD34 Microbeads Followed by Enumeration Using Flow Cytometry.

Burylo AM, de Weger VA, Stuurman FE, Beijnen JH, Schellens JHM.

Thromb Haemost. 2017 Dec;117(12):2356-2368. doi: 10.1160/TH17-04-0254. Epub 2017 Dec 6.

PMID:
29212123
10.

EpCAM-based assays for epithelial tumor cell detection in cerebrospinal fluid.

van Bussel MTJ, Pluim D, Bol M, Beijnen JH, Schellens JHM, Brandsma D.

J Neurooncol. 2018 Mar;137(1):1-10. doi: 10.1007/s11060-017-2691-6. Epub 2017 Nov 30. Review.

PMID:
29192390
11.

Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients.

van Andel L, Rosing H, Zhang Z, Hughes L, Kansra V, Sanghvi M, Tibben MM, Gebretensae A, Schellens JHM, Beijnen JH.

Cancer Chemother Pharmacol. 2018 Jan;81(1):47. doi: 10.1007/s00280-017-3474-7.

12.

Molecular Imaging of ABCB1/ABCG2 Inhibition at the Human Blood Brain Barrier using Elacridar and 11C-Erlotinib PET.

Verheijen RB, Yaqub MM, Sawicki E, van Tellingen O, Lammertsma AA, Nuijen B, Schellens JHM, Beijnen JH, Huitema ADR, Hendrikse NH, Steeghs N.

J Nucl Med. 2017 Nov 24. pii: jnumed.117.195800. doi: 10.2967/jnumed.117.195800. [Epub ahead of print]

PMID:
29175983
13.

Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs.

Herbrink M, de Vries N, Rosing H, Huitema ADR, Nuijen B, Schellens JHM, Beijnen JH.

Biomed Chromatogr. 2018 Apr;32(4). doi: 10.1002/bmc.4147. Epub 2017 Dec 19.

PMID:
29165815
14.

P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice.

Wang J, Gan C, Sparidans RW, Wagenaar E, van Hoppe S, Beijnen JH, Schinkel AH.

Pharmacol Res. 2018 Mar;129:414-423. doi: 10.1016/j.phrs.2017.11.006. Epub 2017 Nov 14.

PMID:
29155017
15.

ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors.

de Gooijer MC, Buil LCM, Beijnen JH, van Tellingen O.

Invest New Drugs. 2017 Nov 17. doi: 10.1007/s10637-017-0539-8. [Epub ahead of print]

PMID:
29147815
16.

PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.

Geenen JJJ, Linn SC, Beijnen JH, Schellens JHM.

Clin Pharmacokinet. 2018 Apr;57(4):427-437. doi: 10.1007/s40262-017-0587-4. Review.

PMID:
29063517
17.

Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of Dexamphetamine in human plasma.

Herbrink M, Thijssen B, Hillebrand MJX, Rosing H, Schellens JHM, Nuijen B, Beijnen JH.

J Pharm Biomed Anal. 2018 Jan 30;148:259-264. doi: 10.1016/j.jpba.2017.10.009. Epub 2017 Oct 18.

PMID:
29059615
18.

An LC-MS/MS method for quantification of the active abiraterone metabolite Δ(4)-abiraterone (D4A) in human plasma.

van Nuland M, Rosing H, de Vries J, Ovaa H, Schellens JHM, Beijnen JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Nov 15;1068-1069:119-124. doi: 10.1016/j.jchromb.2017.10.033. Epub 2017 Oct 16.

PMID:
29059586
19.

Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization.

Verheijen RB, Swart LE, Beijnen JH, Schellens JHM, Huitema ADR, Steeghs N.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1171-1178. doi: 10.1007/s00280-017-3463-x. Epub 2017 Oct 19.

20.

DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update.

Henricks LM, Opdam FL, Beijnen JH, Cats A, Schellens JHM.

Ann Oncol. 2017 Dec 1;28(12):2915-2922. doi: 10.1093/annonc/mdx411.

PMID:
29045513
21.

Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients.

van Andel L, Rosing H, Zhang Z, Hughes L, Kansra V, Sanghvi M, Tibben MM, Gebretensae A, Schellens JHM, Beijnen JH.

Cancer Chemother Pharmacol. 2018 Jan;81(1):39-46. doi: 10.1007/s00280-017-3455-x. Epub 2017 Oct 17. Erratum in: Cancer Chemother Pharmacol. 2017 Nov 27;:.

22.

A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir.

de Weger VA, Stuurman FE, Hendrikx JJMA, Moes JJ, Sawicki E, Huitema ADR, Nuijen B, Thijssen B, Rosing H, Keessen M, Mergui-Roelvink M, Beijnen JH, Schellens JHM, Marchetti S.

Eur J Cancer. 2017 Nov;86:217-225. doi: 10.1016/j.ejca.2017.09.010. Epub 2017 Oct 12.

PMID:
29031170
23.

Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice.

de Groot JS, van Diest PJ, van Amersfoort M, Vlug EJ, Pan X, Ter Hoeve ND, Rosing H, Beijnen JH, Youssef SA, de Bruin A, Jonkers J, van der Wall E, Derksen PWB.

Oncotarget. 2017 Jun 15;8(37):60750-60763. doi: 10.18632/oncotarget.18490. eCollection 2017 Sep 22.

24.

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study.

Dorlo TPC, Kip AE, Younis BM, Ellis SJ, Alves F, Beijnen JH, Njenga S, Kirigi G, Hailu A, Olobo J, Musa AM, Balasegaram M, Wasunna M, Karlsson MO, Khalil EAG.

J Antimicrob Chemother. 2017 Nov 1;72(11):3131-3140. doi: 10.1093/jac/dkx283.

25.

The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors.

de Gooijer MC, Zhang P, Weijer R, Buil LCM, Beijnen JH, van Tellingen O.

Int J Cancer. 2018 Jan 15;142(2):381-391. doi: 10.1002/ijc.31052. Epub 2017 Oct 4.

PMID:
28921565
26.

Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study.

van der Hiel B, Haanen JBAG, Stokkel MPM, Peeper DS, Jimenez CR, Beijnen JH, van de Wiel BA, Boellaard R, van den Eertwegh AJM; REPOSIT study group.

BMC Cancer. 2017 Sep 15;17(1):649. doi: 10.1186/s12885-017-3626-5.

27.

Clinical trial simulations in paediatric oncology: A feasibility study from the Innovative Therapies for Children with Cancer Consortium.

Janssen JM, Zwaan CM, Schellens JHM, Beijnen JH, Huitema ADR.

Eur J Cancer. 2017 Nov;85:78-85. doi: 10.1016/j.ejca.2017.07.050. Epub 2017 Sep 9.

PMID:
28892776
28.

Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).

Kort A, van Hoppe S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.

Mol Pharm. 2017 Oct 2;14(10):3258-3268. doi: 10.1021/acs.molpharmaceut.7b00257. Epub 2017 Sep 19.

PMID:
28880088
29.

Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction.

Retmana IA, Wang J, Schinkel AH, Schellens JHM, Beijnen JH, Sparidans RW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Sep 1;1061-1062:300-305. doi: 10.1016/j.jchromb.2017.07.034. Epub 2017 Jul 23.

30.

Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial.

Verheijen RB, Atrafi F, Schellens JHM, Beijnen JH, Huitema ADR, Mathijssen RHJ, Steeghs N.

Clin Pharmacokinet. 2018 May;57(5):637-644. doi: 10.1007/s40262-017-0582-9.

PMID:
28762135
31.

Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.

Kip AE, Schellens JHM, Beijnen JH, Dorlo TPC.

Clin Pharmacokinet. 2018 Feb;57(2):151-176. doi: 10.1007/s40262-017-0570-0. Review.

32.

Fixed Dosing of Monoclonal Antibodies in Oncology.

Hendrikx JJMA, Haanen JBAG, Voest EE, Schellens JHM, Huitema ADR, Beijnen JH.

Oncologist. 2017 Oct;22(10):1212-1221. doi: 10.1634/theoncologist.2017-0167. Epub 2017 Jul 28. Review.

PMID:
28754722
33.

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.

Verheijen RB, Yu H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR.

Clin Pharmacol Ther. 2017 Nov;102(5):765-776. doi: 10.1002/cpt.787. Epub 2017 Sep 7. Review.

34.

Improving the solubility of nilotinib through novel spray-dried solid dispersions.

Herbrink M, Schellens JHM, Beijnen JH, Nuijen B.

Int J Pharm. 2017 Aug 30;529(1-2):294-302. doi: 10.1016/j.ijpharm.2017.07.010. Epub 2017 Jul 8.

PMID:
28689964
35.

Liquid chromatography-tandem mass spectrometry assay to quantify plitidepsin in human plasma, whole blood and urine.

van Andel L, Rosing H, Fudio S, Avilés P, Tibben MM, Gebretensae A, Schellens JHM, Beijnen JH.

J Pharm Biomed Anal. 2017 Oct 25;145:137-143. doi: 10.1016/j.jpba.2017.06.013. Epub 2017 Jun 21.

PMID:
28662481
36.

BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies.

van Brummelen EMJ, de Boer A, Beijnen JH, Schellens JHM.

Oncologist. 2017 Jul;22(7):864-872. doi: 10.1634/theoncologist.2017-0031. Epub 2017 Jun 2. Review.

PMID:
28576857
37.

Gait dynamics to optimize fall risk assessment in geriatric patients admitted to an outpatient diagnostic clinic.

Kikkert LHJ, de Groot MH, van Campen JP, Beijnen JH, Hortobágyi T, Vuillerme N, Lamoth CCJ.

PLoS One. 2017 Jun 2;12(6):e0178615. doi: 10.1371/journal.pone.0178615. eCollection 2017.

38.

High-Tech Drugs in Creaky Formulations.

Herbrink M, Nuijen B, Schellens JHM, Beijnen JH.

Pharm Res. 2017 Sep;34(9):1751-1753. doi: 10.1007/s11095-017-2185-4. Epub 2017 May 30.

PMID:
28560695
39.

Development and Validation of an LC-MS/MS Method for the Simultaneous Quantification of Abiraterone, Enzalutamide, and Their Major Metabolites in Human Plasma.

van Nuland M, Hillebrand MJX, Rosing H, Schellens JHM, Beijnen JH.

Ther Drug Monit. 2017 Jun;39(3):243-251. doi: 10.1097/FTD.0000000000000387.

PMID:
28490047
40.

Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.

Meulendijks D, Henricks LM, Jacobs BAW, Aliev A, Deenen MJ, de Vries N, Rosing H, van Werkhoven E, de Boer A, Beijnen JH, Mandigers CMPW, Soesan M, Cats A, Schellens JHM.

Br J Cancer. 2017 May 23;116(11):1415-1424. doi: 10.1038/bjc.2017.94. Epub 2017 Apr 20.

PMID:
28427087
41.

The G2 checkpoint-a node-based molecular switch.

de Gooijer MC, van den Top A, Bockaj I, Beijnen JH, Würdinger T, van Tellingen O.

FEBS Open Bio. 2017 Mar 4;7(4):439-455. doi: 10.1002/2211-5463.12206. eCollection 2017 Apr.

42.

Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer.

van Andel L, Zhang Z, Lu S, Kansra V, Agarwal S, Hughes L, Tibben MM, Gebretensae A, Lucas L, Hillebrand MJX, Rosing H, Schellens JHM, Beijnen JH.

Invest New Drugs. 2017 Dec;35(6):751-765. doi: 10.1007/s10637-017-0451-2. Epub 2017 Mar 16.

43.

Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation.

van Hoppe S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.

Pharmacol Res. 2017 Jun;120:43-50. doi: 10.1016/j.phrs.2017.01.035. Epub 2017 Mar 10.

PMID:
28288939
44.

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing.

Verheijen RB, Beijnen JH, Schellens JHM, Huitema ADR, Steeghs N.

Clin Pharmacokinet. 2017 Sep;56(9):987-997. doi: 10.1007/s40262-017-0510-z. Review.

45.

Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II.

Nijenhuis CM, Lucas L, Rosing H, Huitema ADR, Mergui-Roelvink M, Jamieson GC, Fox JA, Mould DR, Schellens JHM, Beijnen JH.

Invest New Drugs. 2017 Aug;35(4):478-490. doi: 10.1007/s10637-017-0428-1. Epub 2017 Jan 31.

PMID:
28138829
46.

Pharmacokinetics and excretion of 14C-Plitidepsin in patients with advanced cancer.

van Andel L, Fudio S, Rosing H, Munt S, Miguel-Lillo B, González I, Tibben MM, de Vries N, de Vries Schultink AHM, Schellens JHM, Beijnen JH.

Invest New Drugs. 2017 Oct;35(5):589-598. doi: 10.1007/s10637-017-0432-5. Epub 2017 Jan 23.

PMID:
28111728
47.

Fast and Adequate Liquid Chromatography-Tandem Mass Spectrometric Determination of Z-endoxifen Serum Levels for Therapeutic Drug Monitoring.

de Krou S, Rosing H, Nuijen B, Schellens JH, Beijnen JH.

Ther Drug Monit. 2017 Apr;39(2):132-137. doi: 10.1097/FTD.0000000000000372.

PMID:
28045782
48.

Volumetric absorptive microsampling (VAMS) as an alternative to conventional dried blood spots in the quantification of miltefosine in dried blood samples.

Kip AE, Kiers KC, Rosing H, Schellens JHM, Beijnen JH, Dorlo TPC.

J Pharm Biomed Anal. 2017 Feb 20;135:160-166. doi: 10.1016/j.jpba.2016.12.012. Epub 2016 Dec 9.

PMID:
28033553
49.

Pharmaceutical development of an amorphous solid dispersion formulation of elacridar hydrochloride for proof-of-concept clinical studies.

Sawicki E, Schellens JH, Beijnen JH, Nuijen B.

Drug Dev Ind Pharm. 2017 Apr;43(4):584-594. doi: 10.1080/03639045.2016.1274901. Epub 2017 Jan 8.

PMID:
28010129
50.

An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome.

de Vries Schultink AH, Alexi X, van Werkhoven E, Madlensky L, Natarajan L, Flatt SW, Zwart W, Linn SC, Parker BA, Wu AH, Pierce JP, Huitema AD, Beijnen JH.

Breast Cancer Res Treat. 2017 Feb;161(3):567-574. doi: 10.1007/s10549-016-4083-6. Epub 2016 Dec 22.

Supplemental Content

Loading ...
Support Center